220 related articles for article (PubMed ID: 32932224)
41. Higher incidence rates than previously known in tenosynovial giant cell tumors.
Mastboom MJL; Verspoor FGM; Verschoor AJ; Uittenbogaard D; Nemeth B; Mastboom WJB; Bovée JVMG; Dijkstra PDS; Schreuder HWB; Gelderblom H; Van de Sande MAJ;
Acta Orthop; 2017 Dec; 88(6):688-694. PubMed ID: 28787222
[TBL] [Abstract][Full Text] [Related]
42. Tenosynovial giant cell tumors (TGCT): molecular biology, drug targets and non-surgical pharmacological approaches.
Spierenburg G; van der Heijden L; van Langevelde K; Szuhai K; Bovée JVGM; van de Sande MAJ; Gelderblom H
Expert Opin Ther Targets; 2022 Apr; 26(4):333-345. PubMed ID: 35443852
[TBL] [Abstract][Full Text] [Related]
43. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
44. Updates on the Treatment of Tenosynovial Giant Cell Tumor.
Chan AS; Katiyar V; Dy P; Singh V
Hematol Oncol Stem Cell Ther; 2023 May; 16(4):307-315. PubMed ID: 37363972
[TBL] [Abstract][Full Text] [Related]
45. The Patient Perspective on the Impact of Tenosynovial Giant Cell Tumors on Daily Living: Crowdsourcing Study on Physical Function and Quality of Life.
Mastboom MJ; Planje R; van de Sande MA
Interact J Med Res; 2018 Feb; 7(1):e4. PubMed ID: 29475829
[TBL] [Abstract][Full Text] [Related]
46. Characterizing and predicting pathologic spine fractures in myeloma patients with FDG PET/CT and MR imaging.
Mulligan M; Chirindel A; Karchevsky M
Cancer Invest; 2011 Jun; 29(5):370-6. PubMed ID: 21599514
[TBL] [Abstract][Full Text] [Related]
47. Image-guided, intensity-modulated radiotherapy for the treatment of diffuse-type tenosynovial giant cell tumor of the knee: Case report and review of the literature.
Xiang X; Jiang W; Qiu C; Xiao N; Liang J
Medicine (Baltimore); 2021 Jul; 100(28):e26659. PubMed ID: 34260572
[TBL] [Abstract][Full Text] [Related]
48. Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT).
Caldwell TM; Ahn YM; Bulfer SL; Leary CB; Hood MM; Lu WP; Vogeti L; Vogeti S; Kaufman MD; Wise SC; Le Bourdonnec B; Smith BD; Flynn DL
Bioorg Med Chem Lett; 2022 Oct; 74():128928. PubMed ID: 35961460
[TBL] [Abstract][Full Text] [Related]
49. Treatment, recurrence rates and follow-up of Tenosynovial Giant Cell Tumor (TGCT) of the foot and ankle-A systematic review and meta-analysis.
Siegel M; Bode L; Südkamp N; Kühle J; Zwingmann J; Schmal H; Herget GW
PLoS One; 2021; 16(12):e0260795. PubMed ID: 34855875
[TBL] [Abstract][Full Text] [Related]
50. [Role of FDG PET in the staging, recurrence and treatment response to imatinib (Glivec) in patients with gastrointestinal stromal tumors].
Simó Perdigó M; García Garzón JR; Soler Peter M; Pérez Moure G; López Gandul S; Lomeña Caballero FJ
Rev Esp Med Nucl; 2006; 25(2):80-8. PubMed ID: 16759613
[TBL] [Abstract][Full Text] [Related]
51. Patient-reported Symptoms of Tenosynovial Giant Cell Tumors.
Gelhorn HL; Tong S; McQuarrie K; Vernon C; Hanlon J; Maclaine G; Lenderking W; Ye X; Speck RM; Lackman RD; Bukata SV; Healey JH; Keedy VL; Anthony SP; Wagner AJ; Von Hoff DD; Singh AS; Becerra CR; Hsu HH; Lin PS; Tap WD
Clin Ther; 2016 Apr; 38(4):778-93. PubMed ID: 27041409
[TBL] [Abstract][Full Text] [Related]
52. Optimal Treatment for Tenosynovial Giant Cell Tumor of the Hand.
Kitagawa Y; Takai S
J Nippon Med Sch; 2020 Sep; 87(4):184-190. PubMed ID: 32350187
[TBL] [Abstract][Full Text] [Related]
53. The value of liver-based standardized uptake value and other quantitative 18F-FDG PET-CT parameters in neoadjuvant therapy response in patients with locally advanced rectal cancer: correlation with histopathology.
Koç M; Kaya GÇ; Demir Y; Sürücü E; Sarioğlu S; Obuz F; Öztop İ; Görken İB; Sökmen S
Nucl Med Commun; 2015 Sep; 36(9):898-907. PubMed ID: 25969176
[TBL] [Abstract][Full Text] [Related]
54. Treatments of tenosynovial giant cell tumours of the temperomandibular joint: a report of three cases and a review of literature.
Verspoor FGM; Mastboom MJL; Weijs WLJ; Koetsveld AC; Schreuder HWB; Flucke U
Int J Oral Maxillofac Surg; 2018 Oct; 47(10):1288-1294. PubMed ID: 29709323
[TBL] [Abstract][Full Text] [Related]
55. Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT.
Heusch P; Buchbender C; Köhler J; Nensa F; Gauler T; Gomez B; Reis H; Stamatis G; Kühl H; Hartung V; Heusner TA
J Nucl Med; 2014 Mar; 55(3):373-8. PubMed ID: 24504054
[TBL] [Abstract][Full Text] [Related]
56. Image findings of tendon sheaths affected by diffuse tenosynovial giant cell tumors of the skull base.
Zhao SS; Cheng JL; Gao EY; Bai J; Zhang Y
Eur Rev Med Pharmacol Sci; 2023 Mar; 27(6):2571-2579. PubMed ID: 37013775
[TBL] [Abstract][Full Text] [Related]
57. Preoperative adjuvant therapy for locally advanced and recurrent/metastatic gastrointestinal stromal tumors: a retrospective study.
Qi J; Liu HL; Ren F; Liu S; Shi W; Liu WH; Cai GQ; Liao GQ
World J Surg Oncol; 2020 Apr; 18(1):70. PubMed ID: 32264886
[TBL] [Abstract][Full Text] [Related]
58. Distinct extra-articular invasion patterns of diffuse pigmented villonodular synovitis/tenosynovial giant cell tumor in the knee joints.
Kim DE; Kim JM; Lee BS; Kim NK; Lee SH; Bin SI
Knee Surg Sports Traumatol Arthrosc; 2018 Nov; 26(11):3508-3514. PubMed ID: 29637236
[TBL] [Abstract][Full Text] [Related]
59. Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumours using 18fluoro-deoxyglucose-positron emission tomography.
Heinicke T; Wardelmann E; Sauerbruch T; Tschampa HJ; Glasmacher A; Palmedo H
Anticancer Res; 2005; 25(6C):4591-4. PubMed ID: 16334147
[TBL] [Abstract][Full Text] [Related]
60. Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.
Tap WD; Singh AS; Anthony SP; Sterba M; Zhang C; Healey JH; Chmielowski B; Cohn AL; Shapiro GI; Keedy VL; Wainberg ZA; Puzanov I; Cote GM; Wagner AJ; Braiteh F; Sherman E; Hsu HH; Peterfy C; Gelhorn HL; Ye X; Severson P; West BL; Lin PS; Tong-Starksen S
Clin Cancer Res; 2022 Jan; 28(2):298-307. PubMed ID: 34716196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
